---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-019281"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2023-03-10T23:59:59+00:00"
generated_at: "2026-06-18T05:18:12.073309+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara confirms no material SVB exposure; cash runway into 2025 unchanged

## Summary
- $102.3M cash equivalents invested in short-term treasury/corporate bonds, not SVB.
- Operating account at SVB used only for monthly expenses; minimal balance.
- Company does not expect SVB failure to impact operations or liquidity.
- Reiterates cash runway guidance into 2025.

## SEC filing metadata
- accession: 0001213900-23-019281
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2023-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390023019281/0001213900-23-019281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390023019281/ea175044-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-019281
- JSON: https://secwatch.observer/filing/0001213900-23-019281.json
- Plain text: https://secwatch.observer/filing/0001213900-23-019281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.